Contrave Rxs Jump In Q1, But TV Commercial Runs Afoul Of FDA
Executive Summary
Orexigen touts 39% growth in US sales of its obesity drug; agency objects to advertisement for excluding risk information.
You may also be interested in...
Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales
Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.
Orexigen Insists It Can Grow Contrave After Takeda Exit
Beware the Ides of March, especially if you're an investor in the obesity drug market. Orexigen added further evidence that the market is crumbling as it hitched its wagon to a partner that is even worse off.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.